Lv1
56 积分 2025-12-12 加入
The evolving landscape of obesity pharmacotherapy
10小时前
待确认
中国高尿酸血症与痛风诊疗指南(2024)第一部分：对一般痛风患者的建议
11天前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
22天前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
24天前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
24天前
已完结
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
25天前
已完结
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
26天前
已完结
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial
26天前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
27天前
已完结
Survodutide Once Weekly for the Treatment of Adults with Obesity
27天前
已完结
皖公网安备34019202002308
